Eli Lilly's stock fell 8.44% in the past month despite strong business growth, driven by concerns over pricing and acquisition charges. The company leads the obesity and diabetes market with blockbuster drugs Mounjaro and Zepbound, generating $14.9 billion quarterly revenue. Citi raised its price target to $1,600, implying a 45% upside, citing expanding prescriptions, new drug launches, and promising pipeline candidates like retatrutide. Analysts remain mostly bullish, expecting continued revenue growth and upcoming catalysts such as label expansions and international launches.
August's inflation report showed headline inflation steady and core inflation falling to its lowest in over five years, signaling easing price pressures. Despite this positive data, the Federal Reserve is still expected to raise interest rates to con...
The iShares U.S. Pharmaceuticals ETF (IHE) provides focused exposure to the US pharmaceutical sector, heavily weighted towards Johnson & Johnson and Eli Lilly. It benefits from growth drivers like obesity therapies and strong drug pipelines but carri...
Eli Lilly has finalized its acquisition of AtaiBeckley, a clinical-stage biopharmaceutical company focused on developing rapid-acting neuroplastogens for mental health, including treatment-resistant depression. This acquisition aims to introduce inno...
Eli Lilly and NVIDIA both reported strong quarterly results, with Lilly growing 47.7% driven by obesity drugs Mounjaro and Zepbound, and NVIDIA soaring 105.8% on AI data center demand. Lilly focuses on expanding its pharmaceutical portfolio and manuf...
The iShares US Pharmaceuticals ETF (IHE) is rated a hold due to fair valuation and increasing short-term challenges. Its portfolio is heavily concentrated, with 43% in Johnson & Johnson and Eli Lilly, and the top 10 holdings making up 76%. Technical ...
